Sun Pharmaceuticals has hit out at the proposed draft new pharma pricing policy (NPPP), 2011, which can lead to shortage of drugs and severely hurt the interests of domestic industry and patients.

The draft policy only looks in terms of price reduction, which is a short-term approach and neither addresses the needs of the industry nor those of patients. The draft NPPP, 2011 intends to bring 60% of the total domestic pharmaceutical market amounting to nearly Rs 29,000 crore under price control by bringing all the 348 drugs specified in the National List of Essential Medicines 2011 under price control. 

Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×